Minnesota · Nonprofit
Karen Wyckoff Rein in Sarcoma
Karen Wyckoff Rein in Sarcoma (Minnesota) receives grants from 35 organizations whose IRS filings report $1,353,340 to it, the largest being DONOR ADVISED CHARITABLE GIVING INC ($259,750). 14 of them have funded it in more than one year, and 70% of the money arrives through donor-advised or pass-through sponsors rather than from an institution directly.
- Revenue FY2024
- $577k
- Funders on record
- 35
- Grants received
- $1.4M
- Net assets
- $1.0M
What Karen Wyckoff Rein in Sarcoma does
Mission
Our three-pronged mission: educating the public and medical community about sarcomas, supporting sarcoma patients and their loved ones, and funding research directed toward developing new treatments and finding a cure for sarcoma cancers.
As stated on its FY2024 Form 990.
Programs
Rein in Sarcoma (RIS) was started by Karen Wyckoff, a 25-year-old Synovial Sarcoma patient. As she fought this rare cancer, she found that there were three things that she thought needed doing to increase the quality of life and odds of survival for all sarcoma patients. As she started the organization, she developed the mission as it still remains today: We are dedicated to educating the public and medical community about sarcoma, supporting sarcoma patients and their loved ones, and funding research directed toward developing new treatments and finding a cure for sarcoma cancer. Finding Cures for Sarcoma Cancer: RIS has partnered with many top-notch research institutions including: University of Minnesota, Mayo Clinic, Children's Minnesota, University of Calgary, Case Western Reserve and University of Michigan. RIS has funded more than $2.5M in high impact and collaborative research. Eighty seven research funding awards have been made to date. Education: RIS has established and expanded its Sarcoma Scholar Program to educate Medical Students and Advanced Practice students about sarcoma. This program began in 2009 with 2 scholars participating from the University of Minnesota and…
$229,453 spentof which $61,025 as grants100% of program spendingOther program services, not described on the e-filed return.
$0 spent0% of program spending
The 2 programs described on its FY2023 Form 990, listed largest first by expense. Program spending in total: $229,453.
The organization over time
Each line starts at 100 in 2020, so what you read is the shape rather than the size: 150 means half as much again as 2020, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2020 to 2021, from $795k to $1.2M (+55%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
Government-grant reliance: 2020 0% · 2021 2% · 2022 0% · 2023 0%. Grants only. Government contracts and fees sit inside program revenue.
93% of Karen Wyckoff Rein in Sarcoma’s revenue is contributions — more donation-reliant than the typical peer (82% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 3 of the last 5 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Who funds it, year by year
2017 → 2023: the base broadened from 7 funders to 14 funders, grant income rose $132k → $237k.
12 of 35 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 70% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.
From the IRS filings of Karen Wyckoff Rein in Sarcoma’s funders (the co-funder graph). Top 30 of 35 funders by total. Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
Karen Wyckoff Rein in Sarcoma has a broad base — no single funder exceeds 19% of grant income, and it takes 4 funders to reach half.
the vertical line marks half of all grant income — 4 funders to its left
72% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund Karen Wyckoff Rein in Sarcoma.
Largest funder’s share by year: 2017 57% · 2018 44% · 2019 42% · 2020 36% · 2021 30% · 2022 35% · 2023 42% — diversifying over time.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How long its funders stay
41% of Karen Wyckoff Rein in Sarcoma's funders are still giving 3 years after their first grant; 40% give in more than one year at all.
Share of funders still giving k years after their first recorded grant, pooled across every acquisition cohort. A funder counts as retained in a year only if it made a grant that year. Measured to FY2023, the last fiscal year that has finished arriving — a funder cannot be counted as lapsed in a year most filers have not reached.
Where its funders are
70% of Karen Wyckoff Rein in Sarcoma's grant income arrives through donor-advised or pass-through sponsors, whose addresses record where the money is held rather than where the donor is. Of the $410k that is directly attributable, 76% of it comes from funders outside Minnesota, across 8 states.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. $944k arriving through sponsors registered in 9 states is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
Karen Wyckoff Rein in Sarcoma is better cushioned than half of the 13,754 health nonprofits its size.
this organization peer median middle 50% of peers· 13,754 health nonprofits $100k–$1M, FY2024
Organizations like Karen Wyckoff Rein in Sarcoma
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In Minnesota
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
55% of spending goes to programs.
Governance
Public support
97%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Footprint & structure
Files a return copy in 1 state
Screen this organization
A dated, signed PDF of the compliance screen for Karen Wyckoff Rein in Sarcoma: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds Karen Wyckoff Rein in Sarcoma?
- Karen Wyckoff Rein in Sarcoma (Minnesota) receives grants from 35 organizations whose IRS filings report $1,353,340 to it, the largest being DONOR ADVISED CHARITABLE GIVING INC ($259,750). 14 of them have funded it in more than one year, and 70% of the money arrives through donor-advised or pass-through sponsors rather than from an institution directly.
- How many funders does Karen Wyckoff Rein in Sarcoma have?
- IRS filings report 35 organizations giving $1,353,340 in grants to Karen Wyckoff Rein in Sarcoma, 14 of which have funded it in more than one year.
- Who is the largest funder of Karen Wyckoff Rein in Sarcoma?
- DONOR ADVISED CHARITABLE GIVING INC is the largest funder on record, with $259,750 in grants. The full list of funders is on this page.
- How can an organization like Karen Wyckoff Rein in Sarcoma find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in Minnesota. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2024 (financials across 2020–2024), and the filings of 35 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 14, 2026. What this page cannot tell you · view filing